Kura Oncology

KURA NASDAQ
18.09
+0.26
+1.46%
Opening 14:50 08/19 EDT
Open
18.11
Prev Close
17.83
High
18.25
Low
17.94
Volume
66.16K
Avg Vol (3M)
371.44K
52 Week High
21.42
52 Week Low
10.20
% Turnover
0.15%
Market Cap
817.94M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Kura Oncology KURA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
MORE >

Recently

Name
Price
%Change